Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
AB-Biotics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
AB-Biotics's earnings available for a low price, and how does
this compare to other companies in the same industry?
AB-Biotics's earnings are expected to grow significantly at over 20% yearly.
AB-Biotics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
AB-Biotics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
2/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Mr. Sergi Audivert Brugué serves as a Co-Founder, Co-Chief Executive Officer and Director at AB-Biotics SA and served as its Chief Operating Officer. Mr. Audivert serves as Chairman of AB-Biotics S.A. Mr. Audivert serves as a Secretary General and Director of Ability Pharmaceuticals, S.L.
Insufficient data for Sergi to compare compensation growth.
Insufficient data for Sergi to establish whether their remuneration is reasonable compared to companies of similar size in Spain.
Who Are The Major Shareholders In AB-Biotics SA (BME:ABB)?
I am going to take a deep dive into AB-Biotics SA’s (BME:ABB) most recent ownership structure, not a frequent subject of discussion among individual investors. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment. … BME:ABB Ownership Summary August 10th 18
Why You Need To Look At This Factor Before Buying AB-Biotics SA. (BME:ABB)
If you are looking to invest in AB-Biotics SA.’s (BME:ABB), or currently own the stock, then you need to understand its beta in order to understand how it can affect the risk of your portfolio. … ABB's beta implies it may be a stock that investors with high-beta portfolios might find relevant if they wanted to reduce their exposure to market risk, especially during times of downturns. … How ABB's assets could affect its beta An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive.
Who Are The Top Investors In AB-Biotics SA. (BME:ABB)?
In this article, I'm going to take a look at AB-Biotics SA.’s (BME:ABB) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … Insider Ownership Insiders form another group of important ownership types as they manage the company's operations and decide the best use of capital. … Thus, investors not need worry too much about the consequences of these holdings.Next Steps: ABB's considerably high level of institutional ownership calls for further analysis into its margin of safety.
Did AB-Biotics SA.'s (BME:ABB) Recent Earnings Growth Beat The Trend?
After reading AB-Biotics SA.'s (BME:ABB) most recent earnings announcement (30 June 2017), I found it useful to look back at how the company has performed in the past and compare this against the latest numbers. … View our latest analysis for AB-Biotics How ABB fared against its long-term earnings performance and its industry I prefer to use data from the most recent 12 months, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … Each year, for the past five years AB-Biotics's top-line has risen by a mere 9.18%, on average.
AB-Biotics, S.A. operates in the biotechnology industry in Spain. The company offers probiotic products, including cardio metabolic products comprising AB-LIFE, AB LIFE Forte, AB-LIFE Plus, and LipiGO; oral care products that include AB-Dentalac, AB-Dentalac Pro, AB-Dentalac Junior, and AB-Dentisanium; pediatric products, such as AB-Kolicare and AB-Digest Kids; i3.1 gastrointestinal product; gynecology and urological products consisting of AB-Intimus and AB-Cyscare; and dermatology and immunology products, which include AB-Immuno and AB-Sakei 65. It also provides genetic tests for behavioral health, pain medicine, and fertility, as well as lab services. AB-Biotics, S.A. was founded in 2004 and is based in Barcelona, Spain.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.